Abstract：
UNASSIGNED: The efficacy of neoadjuvant transarterial chemoembolization (N-TACE) in resectable hepatocellular carcinoma (HCC) remains open to debate. While N-TACE may reduce tumor size, its impact on long-term outcomes is inconclusive.
UNASSIGNED: This meta-analysis reviewed studies on N-TACE before surgical resection vs. liver resection (LR) single large hepatocellular carcinoma (SLHCC) up to March 2023 from four online databases.
UNASSIGNED: Five studies with 1,556 patients were analyzed. No significant differences between N-TACE and LR groups were observed in 1-, 3-, or 5-year overall survival (OS) and disease-free survival (DFS). No significant differences were noted in intraoperative blood loss between groups. Subgroup analysis showed favorable 1-, 3-, and 5-year OS with combination chemotherapy N-TACE (combination group), and better 1-year OS in the LR group with single-agent chemotherapy N-TACE (single-agent group). Five-year DFS favored LR in the single-agent group, and N-TACE in the combination group.
UNASSIGNED: Managing SLHCC requires intricate considerations, and the treatment strategies for this challenging subgroup of HCC need to be improved. The influence of N-TACE on long-term survival depends on the specific chemotherapy regimen employed, and its impact on intraoperative blood loss in SLHCC appears limited.
UNASSIGNED: This meta-analysis reviewed studies on N-TACE before surgical resection vs. liver resection (LR) single large hepatocellular carcinoma (SLHCC) up to March 2023 from four online databases.
UNASSIGNED: Five studies with 1,556 patients were analyzed. No significant differences between N-TACE and LR groups were observed in 1-, 3-, or 5-year overall survival (OS) and disease-free survival (DFS). No significant differences were noted in intraoperative blood loss between groups. Subgroup analysis showed favorable 1-, 3-, and 5-year OS with combination chemotherapy N-TACE (combination group), and better 1-year OS in the LR group with single-agent chemotherapy N-TACE (single-agent group). Five-year DFS favored LR in the single-agent group, and N-TACE in the combination group.
UNASSIGNED: Managing SLHCC requires intricate considerations, and the treatment strategies for this challenging subgroup of HCC need to be improved. The influence of N-TACE on long-term survival depends on the specific chemotherapy regimen employed, and its impact on intraoperative blood loss in SLHCC appears limited.
摘要：
■新辅助经肝动脉化疗栓塞（N-TACE）在可切除的肝细胞癌（HCC）中的疗效仍存在争议。虽然N-TACE可以减小肿瘤大小，其对长期结果的影响尚无定论。
■这项荟萃分析回顾了手术切除前N-TACE的研究与到2023年3月，来自四个在线数据库的肝切除术（LR）单个大肝细胞癌（SLHCC）。
■分析了5项包含1,556名患者的研究。N-TACE和LR组之间在1-，3-,或5年总生存期（OS）和无病生存期（DFS）。两组之间的术中失血量没有显着差异。亚组分析显示有利的1-，3-,联合化疗N-TACE（联合组）的5年OS，单药化疗N-TACE（单药组）LR组的1年OS较好。五年DFS在单代理人组中偏爱LR，和N-TACE在组合组中。
■管理SLHCC需要复杂的考虑因素，对于这个具有挑战性的HCC亚组的治疗策略需要改进。N-TACE对长期生存的影响取决于所采用的特定化疗方案，其对SLHCC术中失血的影响似乎有限。
■这项荟萃分析回顾了手术切除前N-TACE的研究与到2023年3月，来自四个在线数据库的肝切除术（LR）单个大肝细胞癌（SLHCC）。
■分析了5项包含1,556名患者的研究。N-TACE和LR组之间在1-，3-,或5年总生存期（OS）和无病生存期（DFS）。两组之间的术中失血量没有显着差异。亚组分析显示有利的1-，3-,联合化疗N-TACE（联合组）的5年OS，单药化疗N-TACE（单药组）LR组的1年OS较好。五年DFS在单代理人组中偏爱LR，和N-TACE在组合组中。
■管理SLHCC需要复杂的考虑因素，对于这个具有挑战性的HCC亚组的治疗策略需要改进。N-TACE对长期生存的影响取决于所采用的特定化疗方案，其对SLHCC术中失血的影响似乎有限。
